HC Wainwright Comments on Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Lineage Cell Therapeutics in a research note issued to investors on Tuesday, March 11th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.01) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.06) EPS.

Several other analysts have also recently issued reports on the stock. Maxim Group reduced their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. D. Boral Capital reissued a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday. Finally, B. Riley reduced their price objective on Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $4.20.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $0.52 on Thursday. Lineage Cell Therapeutics has a 52 week low of $0.48 and a 52 week high of $1.61. The stock’s fifty day moving average price is $0.60. The stock has a market capitalization of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Fort Sheridan Advisors LLC boosted its holdings in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after acquiring an additional 23,000 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new position in Lineage Cell Therapeutics during the 4th quarter worth approximately $29,000. HighTower Advisors LLC raised its stake in shares of Lineage Cell Therapeutics by 49.5% during the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after buying an additional 19,100 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Lineage Cell Therapeutics by 35.5% in the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after buying an additional 18,053 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in shares of Lineage Cell Therapeutics by 312.2% in the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock valued at $44,000 after buying an additional 65,864 shares in the last quarter. 62.47% of the stock is owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.